Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00571142

Enrollment

Registered

2007-12-11

Start date

2007-11-30

Completion date

2008-02-29

Last updated

2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Diabetic Macular Edema

Keywords

edema, retinal thickness, diabetic retinopathy

Brief summary

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Interventions

PROCEDUREBevacizumab + Pars plana vitrectomy

2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.

PROCEDUREBevacizumab + pars plana vitrectomy

2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Older than 25 yo * Diffuse diabetic macular edema with or without previous treatment

Exclusion criteria

* Another retinal disease * Pregnancy

Design outcomes

Primary

Measure	Time frame
Retinal thickness	3 months

Secondary

Measure	Time frame
Visual acuity	3 months

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026